Get started
Author

Leah Cream

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2017 · George Somlo, Paul H. Frankel, et al. · Clinical Cancer Research · 96
Biology of Bone Metastases: Causes and Consequences
2007 · Harold A. Harvey, Leah von Reyn Cream · Clinical Breast Cancer · 44
Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients
2022 · Kathleen M. Sturgeon, Amanda M. Smith, et al. · BMC Sports Science Medicine and Rehabilitation · 43
PDF
Predicting therapy response in live tumor cells isolated with the flexible micro spring array device
2013 · Jean-Nicolas Gallant, Elizabeth M. Matthew, et al. · Cell Cycle · 21
PDF
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
2014 · George Somlo, Paul Henry Frankel, et al. · Journal of Clinical Oncology · 17
Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma
2020 · Joseph A. Lewcun, Colette Pameijer, et al. · International Journal of Surgery Case Reports · 16
PDF
Testing the acceptability and feasibility of a tablet-based supportive cancer platform for patients with metastatic breast cancer
2021 · Kathryn H. Schmitz, Erica Schleicher, et al. · Journal of Cancer Survivorship · 11
Developing “Nurse AMIE”: A tablet‐based supportive care intervention for women with metastatic breast cancer
2019 · Kathryn H. Schmitz, Xiaochen Zhang, et al. · Psycho-Oncology · 11
A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer
2018 · Megan Wheelden, Leah Cream, et al. · Case Reports in Oncological Medicine · 11
PDF
Update on Clinical Trials: Genetic Targets in Breast Cancer
2012 · Bora Lim, Leah V. Cream, et al. · Advances in experimental medicine and biology · 11
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
2015 · George Somlo, Paul Henry Frankel, et al. · Journal of Clinical Oncology · 9
Abstract P4-10-25: Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer
2020 · Elizabeth O’Day, Kim Leitzel, et al. · Cancer Research · 7
Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial
2020 · Prashanth Moku, Lois Shepherd, et al. · Cancer · 6
PDF
Sirolimus in unmanipulated haploidentical cell transplantation
2008 · L von Reyn Cream, W C Ehmann, et al. · Bone Marrow Transplantation · 6
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
2018 · Kim Leitzel, Suhail M. Ali, et al. · Journal of Clinical Oncology · 4
P14.07 Multi-agent vs. single-agent intra-ventricular chemotherapy for patients with neoplastic meningitis: evidence supporting a new paradigm
2017 · R. Eby, B. Zacharia, et al. · Neuro-Oncology · 2
PDF
Association Of Step Counts With Symptom Burden In Metastatic Breast Cancer Patients
2021 · Brett R. Gordon, Kathryn H. Schmitz, et al. · Medicine & Science in Sports & Exercise · 1
Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial
2019 · PR Moku, LE Shepherd, et al. · Cancer Research · 1
UGT2B17 deletion polymorphism and exemestane-induced toxicity.
2018 · Elizabeth Packard, Cynthia Campbell-Baird, et al. · Journal of Clinical Oncology · 1
Cmet-37. Safety and Efficacy of Intraventricular Biologic Agents as Part of a Multi-agent Intraventricular Treatment Regimen for Patients With Neoplastic Meningitis
2017 · Aaron Bernstein, Oliver Mrowczynski, et al. · Neuro-Oncology · 1
Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2023 · George Somlo, Paul H. Frankel, et al.
Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2023 · George Somlo, Paul H. Frankel, et al.
Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2023 · George Somlo, Paul H. Frankel, et al.
Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2023 · George Somlo, Paul H. Frankel, et al.
Data from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
2023 · George Somlo, Paul H. Frankel, et al.
Works count: 36
Citation count: 319
H-index: 10
I10-index: 10
Year
Topic
Type